Rxi Pharmaceuticals (NASDAQ:RXII) On Thursday March 31, 2016 Rxi Pharmaceuticals announced that it had received a patent from the United States Patent and Trademark Office — USPTO — for the company’s sd-rxRNA technology platform that covers CTGF — Connective Tissue Growth Factor. In essence the patent covers the company’s lead clinical product RXI-109, which is … Read more
Rxi Pharmaceuticals (NASDAQ:RXII) On October 15, 2015 Rxi Pharmaceuticals announced positive phase 2a results for its RXI-109 compound. The trial, known as RXI-109-1402, was comparing RXI-109 treated scars against scars that were revised by surgery — control group. To test out dosing though Rxi gave one cohort of patients 5 mg/cm of RXI-109 while another … Read more
Rxi Pharmaceuticals (NASDAQ:RXII) On August 31, 2015 Rxi announced that the 30-day review period for its IND of RXI-109 for scarring of macular degeneration has passed its review period and the IND is now active. The whole point of the 30-day review period is for the FDA to look at pre-clinical data and conclude whether … Read more
Rxi Pharmaceuticals Corp (NASDAQ: RXII) Rxi Pharmaceuticals last week on March 23, 2015 presented at the 73rd Annual Academy of Dermatology in which the company reported positive progress on clinical trial updates for its dermatology programs. The clinical trial with RXI-109-1301 phase 2a enrolled patients to be tested for hypertrophic scars on the abdomen only. … Read more